Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report

EGFR)-targeted drugs have been the first-line treatment for patients with EGFR-mutant non-small cell lung cancer (NSCLC), especially exon 19 deletions and L858R mutation in exon 21. However, there is insufficient evidence for other less common types of EGFR mutations, such as delE709_T710insD (del 1...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Ning, Wang, Haoyi, Zhu, Hui, Yan, Weiwei, Jing, Wang, Kong, Li, Zhang, Yan, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752199/
https://www.ncbi.nlm.nih.gov/pubmed/31686847
http://dx.doi.org/10.2147/OTT.S221638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752199/
https://www.ncbi.nlm.nih.gov/pubmed/31686847
http://dx.doi.org/10.2147/OTT.S221638

Ejemplares similares